Detalles de la búsqueda
1.
Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia.
Bioorg Chem
; 134: 106479, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36989958
2.
A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma.
J Nat Prod
; 84(12): 3161-3168, 2021 12 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34806369
3.
Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
Bioorg Chem
; 112: 104968, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34000704
4.
Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity.
Bioorg Chem
; 97: 103671, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32120074
5.
Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
Bioorg Chem
; 94: 103367, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31685258
6.
Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
Bioorg Med Chem Lett
; 29(9): 1060-1064, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30857748
7.
Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
Bioorg Chem
; 89: 102943, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31031018
8.
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Arch Pharm (Weinheim)
; 351(7): e1700369, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29741794
9.
Recent Developments in Androgen Receptor Antagonists.
Arch Pharm (Weinheim)
; 348(11): 757-775, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26462013
10.
Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects.
Eur J Med Chem
; 245(Pt 1): 114913, 2023 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36399923
11.
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Eur J Med Chem
; 229: 114009, 2022 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34839996
12.
Recent development of BTK-based dual inhibitors in the treatment of cancers.
Eur J Med Chem
; 233: 114232, 2022 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35247756
13.
Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy.
J Med Chem
; 65(15): 10393-10407, 2022 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35877176
14.
TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicity.
Theranostics
; 12(6): 2535-2548, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35401826
15.
Overview of piperlongumine analogues and their therapeutic potential.
Eur J Med Chem
; 220: 113471, 2021 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33930801
Resultados
1 -
15
de 15
1
Próxima >
>>